23:43 , May 31, 2018 |  BC Innovations  |  Emerging Company Profile

Oral route for HAE

The team behind Firazyr icatibant has reunited to develop an oral version of the drug that could give hereditary angioedema patients the alternative to injectables they’ve been asking for. Pharvaris B.V. brings together team members...
16:26 , Jan 12, 2018 |  BC Week In Review  |  Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
23:54 , Jan 9, 2018 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
08:00 , Nov 9, 2015 |  BioCentury  |  Finance

HAE maker

The $10.5 billion shopping spree by Shire plc (LSE:SHP; NASDAQ:SHPG) in hereditary angioedema likely has come to an end, as the company expects it now has all the HAE products it needs. The final deal...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

Firazyr icatibant regulatory update

EMA's CHMP said Shire withdrew an application to extend the label of Firazyr icatibant to treat angioedema caused by the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. Shire withdrew the application based on...
07:00 , Apr 1, 2013 |  BioCentury  |  Strategy

Shire sees opportunity

With two ophthalmics deals in as many weeks, Shire plc has revealed the next specialty area in which it wants a foothold. The company believes the small size of the ophthalmic practitioner population - about...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

Firazyr icatibant regulatory update

The Scottish Medicines Consortium recommended the use of Firazyr icatibant from Sanofi on the National Health Service (NHS) in Scotland to treat acute attacks of hereditary angioedema (HAE) in adults - its approved indication. FDA...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Clinical News

Firazyr icatibant regulatory update

FDA approved Firazyr icatibant from Shire to treat acute attacks of hereditary angioedema (HAE) in adults. The company said Firazyr is the first self-administered subcutaneous treatment approved in the U.S. for acute HAE. Shire launched...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

Firazyr icatibant regulatory update

FDA's Pulmonary-Allergy Drugs Advisory Committee voted 12-1 that the efficacy and safety data for Firazyr icatibant from Shire support approval to treat acute attacks of hereditary angioedema (HAE) in adults. The panel also voted 11-1...